Aims This study aimed to compare the efficacy of angiotensin receptor–neprilysin inhibitor
(ARNI) therapy with angiotensin receptor blocker (ARB) therapy for cardiovascular outcomes …

Aims We systematically reviewed the European real‐world evidence (RWE) about sacubitril‐
valsartan for heart failure with reduced ejection fraction. Methods and results Twenty‐one …

Background: PARADIGM-HF demonstrated superiority of sacubitril/valsartan (sac/val) over
enalapril in patients with heart failure with reduced ejection fraction (HFrEF). However …

Heart failure (HF) is a growing health concern in aging societies worldwide.
Sacubitril/valsartan is changing the real-world treatment in the whole spectrum of HF. The …

One of the defining features of heart failure (HF) is neurohormonal activation. The renin-
angiotensin-aldosterone-system (RAAS) and sympathetic nervous system (SNS) cause …

Despite significant therapeutic advances, patients with chronic heart failure (HF) remain at
high risk for HF progression and death. Sacubitril/valsartan (previously known as LCZ696) is …

We conducted a systematic review and meta-analysis to assess all-cause mortality and
heart failure (HF) hospitalization with sacubitril/valsartan (S/V) compared to standard HF …

Background The efficacy and safety of sacubitril/valsartan in patients hospitalized with heart
failure (HF) across the spectrum of left ventricular ejection fraction (EF) has not been …

Purpose Sacubitril/valsartan reduced heart failure (HF) admissions and cardiovascular
mortality in the PARADIGM-HF trial. However, real-life studies are scarce comparing daily …

Little is known about the dosing and tolerability of sacubitril/valsartan (LCZ696; Entresto,
Quebec, Canada) in a nonclinical trial population. This study was conducted to evaluate the …